Moreover, SOX5 was associated with genomic instability, susceptibility to medicines such as azacitidine and distinct mutation patterns. SOX5 suppression in NSCLC cells in vitro impeded proliferation, migration and invasion. These findings collectively emphasize the key function of SOX5 in tumor biology and highlight its potential as a biomarker for cancer diagnosis, prognosis and therapeutic targeting.

2 days ago

Journal • PD(L)-1 Biomarker • Pan tumor

PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

azacitidine

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes (clinicaltrials.gov)

P1/2, N=36, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting

4 days ago

Enrollment closed

Venclexta (venetoclax) • Onureg (azacitidine oral)

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy (clinicaltrials.gov)

P2, N=57, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed

4 days ago

Trial completion

azacitidine • sirolimus

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=53, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

4 days ago

Trial suspension

Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. (PubMed, Trials)

This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML.

5 days ago

Journal

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1)

TP53 mutation • FLT3-ITD mutation

Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome. (PubMed, J Cell Biochem)

We uncovered 31 potential key genes showing differential early responses to DAC treatment in TP53-mutant versus wild-type cells, which may be associated with resistance development. This study revealed the potential molecular mechanisms of TP53 gene locus mutation in DAC-treated MDS.

5 days ago

Journal

TP53 (Tumor protein P53) • LGALS1 (Galectin 1)

TP53 mutation

decitabine

ASCERTAIN-V: Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) (clinicaltrials.gov)

P1/2, N=101, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Dec 2025 --> Dec 2026

6 days ago

Trial completion date

Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma (clinicaltrials.gov)

P1/2, N=8, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Oct 2025 --> Aug 2026

6 days ago

Trial primary completion date • Checkpoint inhibition • IO biomarker

CD4 (CD4 Molecule)

Opdivo (nivolumab) • Inqovi (decitabine/cedazuridine)

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission (clinicaltrials.gov)

P2, N=34, Active, not recruiting, Bristol-Myers Squibb | N=78 --> 34

6 days ago

Enrollment change

Onureg (azacitidine oral)

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (clinicaltrials.gov)

P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Dec 2025 --> Jul 2026

9 days ago

Trial completion date

Imfinzi (durvalumab) • guadecitabine (SGI-110)

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML. (PubMed, Blood Adv)

To improve the tolerability of post-transplant maintenance and outcomes despite poor risk disease genetics, we conducted a phase 1 study of venetoclax/FluBu2 RIC transplantation with tacrolimus/methotrexate GVHD prophylaxis followed by all-oral venetoclax/decitabine-cedazuridine (ven/dec-c) maintenance in poor-risk MDS/AML patients (N=30). PROs assessed in first 6-months of maintenance were stable except for emotional function, which improved (P=0.008). Trial is registered at clinicaltrials.gov/NCT03613532.

9 days ago

Journal

TP53 (Tumor protein P53)

TP53 mutation

Venclexta (venetoclax) • methotrexate • Inqovi (decitabine/cedazuridine)

12d

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma (clinicaltrials.gov)

P2, N=21, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

12 days ago

Trial completion date • Trial primary completion date

lenalidomide • Onureg (azacitidine oral)